Technical analysis of GRI Bio, Inc. (GRI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Price Performance
| 1 month | +5.85% |
| 3 months | -3.72% |
| Year-to-date | -73.81% |
| 1 year | -96.63% |
| 3 years | -100.00% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $64.12 |
| 52-week Low | $1.36 |
| Avg Volume (90d) | 255K |
Technical Indicators
| SMA 50 | $1.74 |
| SMA 200 | $5.27 |
| 30-day Volatility (annualised) | 177.2% |
| Price vs SMA 50 | +4.3% |
| Price vs SMA 200 | -65.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $47.60 | |
| 2025-11 | $56.00 | +17.6% |
| 2025-12 | $6.91 | -87.7% |
| 2026-01 | $3.26 | -52.8% |
| 2026-02 | $2.55 | -21.8% |
| 2026-03 | $2.29 | -10.2% |
| 2026-04 | $2.18 | -4.8% |
| 2026-05 | $2.06 | -5.5% |
| 2026-06 | $1.77 | -14.1% |
| 2026-07 | $1.38 | -22.0% |
| 2026-08 | $1.92 | +39.1% |
| 2026-09 | $1.81 | -5.7% |
Price
| Price | $1.81 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.48 |
| EV / EBITDA | 1.10 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 10.30 |